Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Vaccines

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 83 articles:
HTML format
Text format



Single Articles


    July 2019
  1. ADEPOJU P
    The yellow fever vaccination certificate loophole in Nigeria.
    Lancet. 2019;394:203-204.
    PubMed     Text format    


  2. SCHUERMAN L
    RTS,S malaria vaccine could provide major public health benefits.
    Lancet. 2019 Jul 9. pii: S0140-6736(19)31567.
    PubMed     Text format    


  3. NAKKAZI E
    Apply to trial Ebola vaccines in DR Congo, says ministry.
    Lancet. 2019;394:15-16.
    PubMed     Text format    


    June 2019
  4. DROLET M, Benard E, Perez N, Brisson M, et al
    Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.
    Lancet. 2019 Jun 26. pii: S0140-6736(19)30298.
    PubMed     Text format     Abstract available


  5. DE SANJOSE S, Delany-Moretlwe S
    HPV vaccines can be the hallmark of cancer prevention.
    Lancet. 2019 Jun 26. pii: S0140-6736(19)30549.
    PubMed     Text format    


  6. MORI Y, Katasako A, Matsunaga S, Matono T, et al
    Tetanus: remember to vaccinate.
    Lancet. 2019;393:2331.
    PubMed     Text format    


  7. THOMPSON KM
    Polio endgame options: will we have the vaccines needed?
    Lancet. 2019 Jun 4. pii: S0140-6736(19)31294.
    PubMed     Text format    


  8. VAN DAMME P, De Coster I, Bandyopadhyay AS, Revets H, et al
    The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study.
    Lancet. 2019 Jun 4. pii: S0140-6736(19)31279.
    PubMed     Text format     Abstract available


    May 2019
  9. THE LANCET
    Acknowledging the limits of public health solutions.
    Lancet. 2019;393:2100.
    PubMed     Text format    


  10. USHER AD
    Low-cost pneumonia vaccine breaks into global market.
    Lancet. 2019;393:2025-2026.
    PubMed     Text format    


  11. ROBERT A, Funk S, Kucharski AJ
    The measles crisis in Europe-the need for a joined-up approach.
    Lancet. 2019;393:2033.
    PubMed     Text format    


  12. SNIDER CJ, Zaman K, Estivariz CF, Yunus M, et al
    Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial.
    Lancet. 2019 May 16. pii: S0140-6736(19)30503.
    PubMed     Text format     Abstract available


  13. SUTTER RW, Zaffran M
    Addressing the inactivated poliovirus vaccine shortage.
    Lancet. 2019 May 16. pii: S0140-6736(19)30766.
    PubMed     Text format    


  14. DE FIGUEIREDO A, Were F
    Local trends in immunisation coverage across Africa.
    Lancet. 2019;393:1779-1781.
    PubMed     Text format    


    April 2019
  15. ADEPOJU P
    RTS,S malaria vaccine pilots in three African countries.
    Lancet. 2019;393:1685.
    PubMed     Text format    


  16. HAMMITT LL, Etyang AO, Morpeth SC, Ojal J, et al
    Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study.
    Lancet. 2019 Apr 15. pii: S0140-6736(18)33005.
    PubMed     Text format     Abstract available


  17. KLUGMAN KP, Rodgers GL
    Population versus individual protection by pneumococcal conjugate vaccination.
    Lancet. 2019 Apr 15. pii: S0140-6736(19)30039.
    PubMed     Text format    


  18. MOSSER JF, Gagne-Maynard W, Rao PC, Osgood-Zimmerman A, et al
    Mapping diphtheria-pertussis-tetanus vaccine coverage in Africa, 2000-2016: a spatial and temporal modelling study.
    Lancet. 2019 Apr 5. pii: S0140-6736(19)30226.
    PubMed     Text format     Abstract available


    March 2019
  19. NAYAR RK, Nair AT, Shaffi M, Swarnam K, et al
    Methods to overcome vaccine hesitancy.
    Lancet. 2019;393:1203-1204.
    PubMed     Text format    


  20. THE LANCET
    Canada's mandatory vaccination reporting plans.
    Lancet. 2019;393:960.
    PubMed     Text format    


  21. ZHAO F, Qiao Y
    Cervical cancer prevention in China: a key to cancer control.
    Lancet. 2019;393:969-970.
    PubMed     Text format    


  22. MALVY D, McElroy AK, de Clerck H, Gunther S, et al
    Ebola virus disease.
    Lancet. 2019;393:936-948.
    PubMed     Text format     Abstract available


  23. GAUDINSKI MR, Coates EE, Novik L, Widge A, et al
    Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study.
    Lancet. 2019;393:889-898.
    PubMed     Text format     Abstract available


    February 2019
  24. GOSTIN L, Phelan A, Coutinho AG, Eccleston-Turner M, et al
    Ebola in the Democratic Republic of the Congo: time to sound a global alert?
    Lancet. 2019 Feb 1. pii: S0140-6736(19)30243.
    PubMed     Text format    


    January 2019
  25. WILDER-SMITH A, Ooi EE, Horstick O, Wills B, et al
    Dengue.
    Lancet. 2019;393:350-363.
    PubMed     Text format     Abstract available


  26. COHEN PA, Jhingran A, Oaknin A, Denny L, et al
    Cervical cancer.
    Lancet. 2019;393:169-182.
    PubMed     Text format     Abstract available


  27. THE LANCET
    Cervical cancer: unequal progress.
    Lancet. 2019;393:104.
    PubMed     Text format    


  28. SHUCHMAN M
    Logistical challenges in the DR Congo Ebola virus response.
    Lancet. 2019;393:117-118.
    PubMed     Text format    


    November 2018
  29. LARSON HJ
    The state of vaccine confidence.
    Lancet. 2018;392:2244-2246.
    PubMed     Text format    


  30. THE LANCET
    Looking beyond the Decade of Vaccines.
    Lancet. 2018;392:2139.
    PubMed     Text format    


  31. CHANDLER J
    Fighting a polio outbreak in Papua New Guinea.
    Lancet. 2018;392:2155-2156.
    PubMed     Text format    


  32. POWERS AM
    Licensed chikungunya virus vaccine: a possibility?
    Lancet. 2018 Nov 5. pii: S0140-6736(18)32809.
    PubMed     Text format    


  33. REISINGER EC, Tschismarov R, Beubler E, Wiedermann U, et al
    Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.
    Lancet. 2018 Nov 5. pii: S0140-6736(18)32488.
    PubMed     Text format     Abstract available


    October 2018
  34. CLAUDE KM, Underschultz J, Hawkes MT
    Ebola virus epidemic in war-torn eastern DR Congo.
    Lancet. 2018;392:1399-1401.
    PubMed     Text format    


  35. MARKS F, Kim JH, Rakotozandrindrainy R
    Madagascar should introduce typhoid conjugate vaccines now.
    Lancet. 2018;392:1309-1310.
    PubMed     Text format    


    September 2018
  36. ZIMMER BL, Gamble L, Mayer D, Foster R, et al
    Canine rabies vaccination reduces child rabies cases in Malawi.
    Lancet. 2018;392:1115-1116.
    PubMed     Text format    


  37. PRUE G, Baker P, Graham D, Nutting C, et al
    It is time for universal HPV vaccination.
    Lancet. 2018;392:913-914.
    PubMed     Text format    


  38. BURKI T
    Cochrane review methods called into question.
    Lancet. 2018;392:906.
    PubMed     Text format    


  39. HOLT E
    41 000 measles cases in Europe since the beginning of 2018.
    Lancet. 2018;392:724.
    PubMed     Text format    


    August 2018
  40. HAYFLICK L
    Subject of The Vaccine Race offers perspective on errors.
    Lancet. 2018;392:633-634.
    PubMed     Text format    


  41. LEVY Y, Lane C, Piot P, Beavogui AH, et al
    Prevention of Ebola virus disease through vaccination: where we are in 2018.
    Lancet. 2018 Aug 10. pii: S0140-6736(18)31710.
    PubMed     Text format    


  42. THE LANCET
    Vaccine scandal and confidence crisis in China.
    Lancet. 2018;392:360.
    PubMed     Text format    


  43. GREEN A
    HPV vaccine to be offered to boys in England.
    Lancet. 2018;392:374.
    PubMed     Text format    


  44. YUAN X
    China's vaccine production scare.
    Lancet. 2018;392:371.
    PubMed     Text format    


  45. FRASER B
    Measles outbreak in the Americas.
    Lancet. 2018;392:373.
    PubMed     Text format    


    July 2018
  46. BAROUCH DH, Tomaka FL, Wegmann F, Stieh DJ, et al
    Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).
    Lancet. 2018;392:232-243.
    PubMed     Text format     Abstract available


  47. PAVLAKIS GN, Felber BK
    A new step towards an HIV/AIDS vaccine.
    Lancet. 2018;392:192-194.
    PubMed     Text format    


  48. LEWNARD JA
    Ebola virus disease: 11 323 deaths later, how far have we come?
    Lancet. 2018;392:189-190.
    PubMed     Text format    


  49. DEVI S
    Setbacks in the fight to eradicate polio.
    Lancet. 2018;392:201-202.
    PubMed     Text format    


  50. BANYAI K, Estes MK, Martella V, Parashar UD, et al
    Viral gastroenteritis.
    Lancet. 2018;392:175-186.
    PubMed     Text format     Abstract available


    June 2018
  51. GREEN A
    DR Congo: investigational research against Ebola virus.
    Lancet. 2018;391:2308-2309.
    PubMed     Text format    


    May 2018
  52. WINSTON DJ, Mullane KM, Cornely OA, Boeckh MJ, et al
    Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial.
    Lancet. 2018;391:2116-2127.
    PubMed     Text format     Abstract available


  53. CORCORAN B, Clarke A, Barrett T
    Rapid response to HPV vaccination crisis in Ireland.
    Lancet. 2018;391:2103.
    PubMed     Text format    


  54. MACARTNEY K, Gershon AA
    Shingles vaccine after auto-HSCT decreases risk.
    Lancet. 2018;391:2082-2084.
    PubMed     Text format    


  55. KELLY JD, Mukadi P, Dhillon RS
    Beyond vaccines: improving survival rates in the DRC Ebola outbreak.
    Lancet. 2018 May 25. pii: S0140-6736(18)31212.
    PubMed     Text format    


  56. QADRI F, Azad AK, Flora MS, Khan AI, et al
    Emergency deployment of oral cholera vaccine for the Rohingya in Bangladesh.
    Lancet. 2018;391:1877-1879.
    PubMed     Text format    


  57. AGUIAR M
    Dengue vaccination: a more ethical approach is needed.
    Lancet. 2018;391:1769-1770.
    PubMed     Text format    


  58. HARGREAVES S, Nellums LB, Ramsay M, Saliba V, et al
    Who is responsible for the vaccination of migrants in Europe?
    Lancet. 2018;391:1752-1754.
    PubMed     Text format    


    April 2018
  59. THE LANCET
    Addressing decreasing vaccine coverage in the EU.
    Lancet. 2018;391:1638.
    PubMed     Text format    


  60. CHEN S, Li J, Wang D, Fung H, et al
    The hepatitis B epidemic in China should receive more attention.
    Lancet. 2018;391:1572.
    PubMed     Text format    


    March 2018
  61. PENG X, Hu X, Salazar MA
    On reducing the risk of vaccine-associated paralytic poliomyelitis in the global transition from oral to inactivated poliovirus vaccine.
    Lancet. 2018 Mar 28. pii: S0140-6736(18)30483.
    PubMed     Text format    


  62. WATTS G
    New York Challenge sets high bar for HPV vaccination.
    Lancet. 2018;391:1137.
    PubMed     Text format    


  63. METZGER WG, Vivas-Martinez S
    Questionable efficacy of the rVSV-ZEBOV Ebola vaccine.
    Lancet. 2018;391:1021.
    PubMed     Text format    


  64. LONGINI IM, Rottingen JA, Kieny MP, Edmunds WJ, et al
    Questionable efficacy of the rVSV-ZEBOV Ebola vaccine - Authors' reply.
    Lancet. 2018;391:1021-1022.
    PubMed     Text format    


    February 2018
  65. PANG T, Gubler D, Goh DYT, Ismail Z, et al
    Dengue vaccination: a more balanced approach is needed.
    Lancet. 2018;391:654.
    PubMed     Text format    


  66. LARSON HJ
    A global girl gang.
    Lancet. 2018;391:527-528.
    PubMed     Text format    


  67. PAULES CI, Subbarao K
    Influenza vaccination and prevention of cardiovascular disease mortality - Authors' reply.
    Lancet. 2018;391:427-428.
    PubMed     Text format    


  68. CALDEIRA D, Ferreira JJ, Costa J
    Influenza vaccination and prevention of cardiovascular disease mortality.
    Lancet. 2018;391:426-427.
    PubMed     Text format    


  69. THE LANCET
    Yellow fever: a major threat to public health.
    Lancet. 2018;391:402.
    PubMed     Text format    


    January 2018
  70. THE LANCET
    Preparing for seasonal influenza.
    Lancet. 2018;391:180.
    PubMed     Text format    


  71. THE LANCET
    A new vaccine for typhoid control.
    Lancet. 2018;391:96.
    PubMed     Text format    


  72. PETOUSIS-HARRIS H, Paynter J, Morgan J, Saxton P, et al
    Pitfalls of the healthy vaccinee effect - Authors' reply.
    Lancet. 2018;391:123-124.
    PubMed     Text format    


  73. MAHMUD SM, Righolt CH
    Pitfalls of the healthy vaccinee effect.
    Lancet. 2018;391:123.
    PubMed     Text format    


  74. ZAFFRAN M, McGovern M, Hossaini R, Martin R, et al
    The polio endgame: securing a world free of all polioviruses.
    Lancet. 2018;391:11-13.
    PubMed     Text format    


    December 2017
  75. MARQUES ETA, Burke DS
    Tradition and innovation in development of a Zika vaccine.
    Lancet. 2017 Dec 4. pii: S0140-6736(17)33107.
    PubMed     Text format    


  76. GAUDINSKI MR, Houser KV, Morabito KM, Hu Z, et al
    Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials.
    Lancet. 2017 Dec 4. pii: S0140-6736(17)33105.
    PubMed     Text format     Abstract available


  77. MODJARRAD K, Lin L, George SL, Stephenson KE, et al
    Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.
    Lancet. 2017 Dec 4. pii: S0140-6736(17)33106.
    PubMed     Text format     Abstract available


    October 2017
  78. YIN Y
    HPV vaccination in China needs to be more cost-effective.
    Lancet. 2017;390:1735-1736.
    PubMed     Text format    


    September 2017
  79. JIN C, Gibani MM, Moore M, Juel HB, et al
    Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.
    Lancet. 2017 Sep 28. pii: S0140-6736(17)32149.
    PubMed     Text format     Abstract available


  80. FEASEY NA, Levine MM
    Typhoid vaccine development with a human challenge model.
    Lancet. 2017 Sep 28. pii: S0140-6736(17)32407.
    PubMed     Text format    


  81. HUH WK, Joura EA, Giuliano AR, Iversen OE, et al
    Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
    Lancet. 2017 Sep 5. pii: S0140-6736(17)31821.
    PubMed     Text format     Abstract available


  82. DENNY L
    Nine-valent human papillomavirus vaccine: great science, but will it save lives?
    Lancet. 2017 Sep 5. pii: S0140-6736(17)32144.
    PubMed     Text format    


    November 2016
  83. DENNY L, de Sanjose S, Mutebi M, Anderson BO, et al
    Interventions to close the divide for women with breast and cervical cancer between low-income and middle-income countries and high-income countries.
    Lancet. 2016 Nov 1. pii: S0140-6736(16)31795.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: